source
- Abbott nabs FDA approval, CE Mark for implantable cardioverter-defibrillator leadAbbott has received both FDA and CE Mark approval for its UltiSynq defibrillation lead tech, which is designed to deliver both conduction system pacing and defibrillation therapy.
- Capricor boosts manufacturing capacity as FDA decision on DMD cell therapy loomsCapricor Therapeutics, a biotech developing a cell therapy for Duchenne muscular dystrophy, is preparing for an FDA decision expected by late November. The company’s third-quarter operating expens…